secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTEGRA LIFESCIENCES HOLDINGS CORP (IART)
CIK:        0000917520
Form:       8-K
Filed at:   2023-01-10T23:59:59+00:00
Accession:  0000917520-23-000003
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Integra pre-announces Q4 rev ~$397-398M, adj EPS above guidance; FY rev ~$1,557-1,558M
--------------------------------------------------------------------------------

- Q4 2022 revenue expected $397M-$398M, down ~2% reported, up ~3% organic vs Q4 2021.
- Adjusted EPS expected above high end of October guidance range.
- FY2022 revenue expected $1,557M-$1,558M, up ~1% reported, +4% organic.
- Full-year adjusted EPS above high end of October guidance and above midpoint of original Feb guidance.
- Company presenting at JP Morgan Healthcare Conference on Jan 11, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/917520/000091752023000003/0000917520-23-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/917520/000091752023000003/iart-20230110.htm
  HTML page:      https://secwatch.observer/filing/0000917520-23-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer